Sanofi R&D team accelerates blockbuster development efforts — while casting doubt on a heavyweight rival’s plans
When Paul Hudson took the CEO job at Sanofi, it was clear he had one hot hand to play with Dupixent and a legacy pipeline that was both distracted by incremental diabetes work and lacking much by way of exciting new drug programs with blockbuster potential.
Some, but not much.
So he did what any good CEO would do, jumping in after a fallow stretch: stripped out the unappealing and started hunting new deals, all while nurturing the cash cow by adding a slate of new development programs to build that pipeline-in-a-product all the Big Pharmas love.
This article is for premium subscribers only
Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.